Illumina Share Price

Since Kalorama Information last updated our full report on the market for cancer screening, changes in industry abound. Developments that were new two years ago as marketing service products, pharmacogenomic tests and tissue microarrays indicate a greater presence. Some companies that promised much in the past the results were inconclusive. And the newcomers have entered the field.
These changes and others are discussed in Kalorama Information Worldwide Market for the diagnosis of cancer, 4th. Edition. This report by Kalorama diagnosis analyst Shara Rosen, contains detailed data on market segments following SCI for use in cancer diagnosis:
aec Histology / cytology
aec Immunoassays
aec Flow cytometry
aec Rapid tests
aec molecular biology tests
aec Tissue Arrays
aec circulating tumor cells
aec Pharmacognosy

diagnostic tests for cancer screening are obviously more effective than ever. Cancer is more treatable, multiple diagnoses are found in expanded roles, including pharmacognosy to match the targeted treatment for patients and the monitoring of diseases like cancer can be treated over into the field of chronic disease . Kalorama Information Worldwide Market for the diagnosis of cancer, 4th edition is the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data in this report, readers will find:
Lab Immunoassay aec Sales cancer based
aec Volumes Pap
aec Statistics World cons cancer
aec POC Testing
aec Reagents for DNA screening for cancer
aec Markets CTC test
aec Biochip Innovations
aec New Business New approaches
aec "late" companies that do not meet expectations
aec major protein and molecular markers used in tissue staining
aec biomarkers under investigation
aec Acquisitions and mergers
aec State of pharmacogenomic tests
aec Microarray Markets in clinical laboratories
aec Lists of major suppliers and products
aec Unmet needs of the marketplace

The report includes analysis of market testing the following: The cancer profile, CTC, fecal occult blood, PSA, H. pylori, IHC, ISH and tests for specific cancers:
aec Bladder cancer
aec Breast
aec Cervical Cancer
aec colon cancer
aec Lung Cancer
aec Ovarian Cancer
aec Prostate

This latest edition of Kalorama Information study takes a fresh look at all these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
aec Tests for specific cancers, and
aec Tests on cancer in specific segments SCI
This allows the reader to match its own market situation in general.

Contents
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth Market
Test Segments
Geographical Distribution
Market Trends
Mortality rate
Revolutionary Therapeutics
Doctor Factor
Consumer Lobby
Price

Chapter Two: Introduction
Background
Pharmacogenomics
Marketing testing services
Cancer - The diagnosis and disease management
View

CHAPTER III: Market Trends in the marketing of cancer diagnostics
Background
Demographics of cancer, a global phenomenon
Cancer screening in the World:
Screening and management of government programs
United States of America
International
Europe
Mexico
China
India
Refund and marketing.